Development of a homogeneous MAP kinase reporter gene screen for the identification of agonists and antagonists at the CXCR1 chemokine receptor.
Agonist activity at G protein-coupled receptors (GPCRs) that regulate heterotrimeric G proteins of the Galpha(i/o) or Galpha(q) families has been shown to result in activation of the mitogen-activated protein (MAP) kinase cascade. To facilitate compound screening for these classes of GPCR, we have developed a reporter gene that detects the activation of the ternary complex transcription factor Sap1a following MAP kinase activation. In contrast to other reporter gene assays for Galpha(i/o)-coupled GPCRs, the MAP kinase reporter generates an increase in signal in the presence of agonist. The reporter gene has been transfected into Chinese hamster ovary cells to generate a "host" reporter gene-containing cell line. The Galpha(i)-coupled human CXCR1 chemokine receptor was subsequently transfected into this cell line in order to develop a 384-well format screen for both agonists and antagonists of this receptor. Agonists activated the reporter gene with the expected rank order of potency and with similar concentration dependence as seen with the regulation of other signal transduction cascades in mammalian cells: interleukin-8 (IL-8) (pEC(50) = 7.0 +/- 0.1) > GCP-2 (pEC(50) = 6.3 +/- 0.1) > NAP-2 (pEC(50) < 6). CXCR1-mediated activation of MAP kinase was inhibited by pertussis toxin and the MEK inhibitor PD98059, demonstrating that receptor activation of MAP kinase is due to pertussis toxin-sensitive Galpha(i/o)-family G proteins to cause the activation of MEK kinase. Using the 384-well format, assay performance was unaffected by solvent concentrations of 0.5% ethanol, 0.15% glycerol, or 1% DMSO. Signal crosstalk between adjacent wells was less than 1%. The assay exhibited a Z factor of 0.53 and a coefficient of variation of response to repeated application of IL-8 (100 nM) of 15.9%.
Rees
S
S
Molecular Discovery Research Unit, Glaxo Wellcome Medicines Research Centre, Hertfordshire, UK. esr1353@glaxowellcome.co.uk
Martin
D P
DP
Scott
S V
SV
Brown
S H
SH
Fraser
N
N
O'Shaughnessy
C
C
Beresford
I J
IJ
D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000706:statistics & numerical data; D004789:Enzyme Activation; D005419:Flavonoids / Q000494:pharmacology; D017930:Genes, Reporter / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D016209:Interleukin-8 / Q000494:pharmacology; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics* / Q000378:metabolism; D037342:Pertussis Toxin; D023062:Receptors, Interleukin-8A / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000235:genetics; D015398:Signal Transduction; D014162:Transfection; D010566:Virulence Factors, Bordetella / Q000494:pharmacology; D050808:ets-Domain Protein Elk-4
D004268:DNA-Binding Proteins; C494193:ELK4 protein, human; D005419:Flavonoids; D016209:Interleukin-8; D023062:Receptors, Interleukin-8A; D010566:Virulence Factors, Bordetella; D050808:ets-Domain Protein Elk-4; D037342:Pertussis Toxin; D020928:Mitogen-Activated Protein Kinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one